-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
● Interim data from the first 15 patients with measurable lesions who received TST001 (osemitamab) in combination with CAPOX as the first-line treatment for advanced or metastatic gastric cancer and gastroesophageal junction cancer showed that according to the RECIST 1.
Chemotherapy is still the mainstay of treatment for advanced or metastatic gastric cancer and gastroesophageal junction cancer, but its efficacy is limited
On September 13, 2022, Chuangsheng Group (06628.
As of 4 August 2022, a total of 51 patients were enrolled and treated, including 36 patients
All 51 enrolled patients underwent safety and tolerability assessments
These data show that TST001 (osemitamab) combined with CAPOX is used for first-line treatment of Claudin18.
Chemotherapy is still the mainstay of treatment for advanced or metastatic gastric cancer and gastroesophageal junction cancer, but its efficacy is limited